Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2025
Reporting Period: Event date January 21, 2025; Compliance period ends July 21, 2025.
Context: The Company received notification from Nasdaq regarding a failure to maintain the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on listing status compliance.
Material Changes
- Minimum Bid Price Violation: For the 30 consecutive business days ended January 17, 2025, the Company's common stock did not maintain a minimum bid price of $1.00 per share.
- Compliance Period Initiated: Nasdaq granted a 180-calendar-day compliance period ending July 21, 2025, to regain compliance.
- Current Listing Status: The notification does not impact the current listing of the Company's common stock on the Nasdaq Global Select Market at this time.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company intends to actively monitor its bid price during the compliance period.
- The Company plans to take all reasonable measures to regain compliance, which may include implementing a reverse stock split (must be completed no later than ten business days prior to the expiration of the compliance period).
- Alternatively, the Company may seek to transfer its listing to the Nasdaq Capital Market if criteria are met.
Risks and Contingencies:
- Delisting Risk: If the Company fails to regain compliance by July 21, 2025, its common stock is subject to delisting from the Nasdaq Global Market.
- Uncertainty: There is no assurance that the Company will be able to regain or maintain compliance with applicable listing standards.
- Forward-Looking Statements: Statements regarding the ability to regain compliance are subject to substantial risks and uncertainties.
Investor Verification Checklist
- Verify the current trading price of RLMD to assess the gap from the $1.00 minimum bid requirement.
- Monitor upcoming announcements regarding potential reverse stock splits or capital raising activities intended to boost the share price.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial health and liquidity positions not included in this 8-K.
- Track the Company's progress toward the July 21, 2025, compliance deadline.